Monoclonal Antibodies Market 2020 - Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc
Major Companies Covered in this report:-
1 Pfizer Inc.*
2 Novartis AG.
3 Bayer AG.
4 Sanofi S.A.
5 Hoffmann-La Roche AG.
6 Eli Lilly and Co.
7 Merck & Co., Inc.
Request For Sample Copy of the Report @
Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases.
Rising incidence of cancer and other chronic diseases is a major factor that is expected to boost the monoclonal antibodies market growth over the forecast period. According to GLOBOCAN, in 2018, an estimated 43.6% new cases of breast cancer were registered in Asia Pacific. Also, according to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths.
Get up to 30% Discount on this Premium Report @:
Market players are focused on combining monoclonal antibodies with other therapies such as chemotherapy drugs, which is expected to assist the market growth over the forecast period. For instance, combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma was approved in the U.S. in 2018 and in January 2019 in Europe.
Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA) expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Major players operating in the global monoclonal antibodies market include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.
Apply Promo Code “STAYHOME” and Get Up to 30% Discount
If you purchase the report this year:
Buy This Complete A Business Report:
Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Monoclonal Antibodies Market 2020 - Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc here
News-ID: 2236139 • Views: 440
More Releases from busines news
Latest Research Of The Hip Replacement Market 2020 New Opportunities | Depuy Syn …
Coherent Market Insights has recently added a new research report to its mega database of research studies. The research report, titled “Global Hip Replacement Market Report 2020 is latest research report, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Hip Replacement Market. Additionally, the Hip
Cell and Gene Therapy Market 2020 - Amgen, Biogen, BioMarin Pharmaceuticals, Bri …
CMI analyses the Cell and Gene Therapy trends, by country, for a five year review period (2020-2027) forecast period. Our regular clients asked us to produce detailed market segmentation, and this is what you will find here: a report without any unnecessary padding, giving a unique analysis of the sector. Major Companies Covered in this report:- 1 Amgen * 2 Biogen 3 BioMarin Pharmaceuticals 4 Bristol-Myers Squibb Company 5 GlaxoSmithKline 6 Novartis 7 Pfizer Request For Sample Copy of
Ovarian Cancer Drugs Market 2020 - Bristol Myers Squibb Company, Eli Lilly and C …
CMI analyses the Ovarian Cancer Drugs trends, by country, for a five year review period (2020-2027) forecast period. Our regular clients asked us to produce detailed market segmentation, and this is what you will find here: a report without any unnecessary padding, giving a unique analysis of the sector. Major Companies Covered in this report: Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc.,
Lung Cancer Therapeutics Market 2020 - Pfizer, Celgene, F. Hofmann-La Roche, Ast …
CMI analyses the Lung Cancer Therapeutics trends, by country, for a five year review period (2020-2027) forecast period. Our regular clients asked us to produce detailed market segmentation, and this is what you will find here: a report without any unnecessary padding, giving a unique analysis of the sector. Major Companies Covered in this report: Pfizer, Celgene, F. Hofmann-La Roche, AstraZeneca and Eli Lilly. Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/702 Lung
More Releases for Monoclonal
Monoclonal Antibodies Market Outline and Updates..!!
Rising adoption of strategies such as acquisition, collaboration, and license agreement by the market players is expected to bolster the monoclonal antibodies market growth over the forecast period. For instance, in 2018, F. Hoffman-La Roche AG and Kymab Group Ltd entered into a clinical trial agreement to evaluate KY1044 (product of Kymab Group), a human monoclonal antibody, for the treatment of solid tumors. Also, in 2018, Novartis AG entered into
Global Monoclonal Antibody Diagnostic Reagents Market
Antibodies are an essential tool for many applications including flow cytometric analysis, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), immunocytochemistry, western blotting, and immunohistochemistry. Moreover, monoclonal antibodies (MAbs) are significant diagnostic reagent used in microbiological research, biomedical research, and also in diagnosis of various diseases such as HIV, hepatitis, herpes simplex, influenza infections, chlamydia, as well as for the treatment of cancer. Therefore, due to its importance in the clinical application, it
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515 Monoclonal Antibody Custom Service Market – Overview It is estimated that monoclonal antibody custom service market is expected to
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies. In recent years the popularity
Global Monoclonal Antibodies Pipeline Insight 2015
Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality.